Mylan NV (NASDAQ:MYL) Receives $33.06 Consensus Target Price from Analysts

Shares of Mylan NV (NASDAQ:MYL) have received an average rating of “Buy” from the twenty-four analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $32.50.

A number of research firms recently commented on MYL. Raymond James set a $31.00 price objective on Mylan and gave the company a “buy” rating in a report on Wednesday, May 8th. Barclays reiterated a “hold” rating on shares of Bank of Montreal in a report on Tuesday, June 11th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $130.00 price objective (up from $116.00) on shares of Zoetis in a report on Wednesday, June 12th. Mizuho set a $9.00 price objective on Endo International and gave the company a “hold” rating in a report on Tuesday, May 14th. Finally, BMO Capital Markets cut Capital Power from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 8th.

Shares of MYL stock traded up $0.25 during trading hours on Friday, reaching $18.10. The company had a trading volume of 6,094,946 shares, compared to its average volume of 5,996,927. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.51 and a quick ratio of 0.85. The stock has a fifty day simple moving average of $18.28. The firm has a market cap of $9.20 billion, a P/E ratio of 3.95, a price-to-earnings-growth ratio of 0.92 and a beta of 1.76. Mylan has a 12-month low of $16.63 and a 12-month high of $39.59.

Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.03. Mylan had a return on equity of 18.96% and a net margin of 2.14%. The business had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.70 billion. During the same period in the prior year, the business earned $0.96 earnings per share. The business’s revenue was down 7.0% compared to the same quarter last year. As a group, analysts anticipate that Mylan will post 4.27 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in MYL. Vicus Capital raised its stake in shares of Mylan by 5.3% in the first quarter. Vicus Capital now owns 7,874 shares of the company’s stock valued at $223,000 after acquiring an additional 396 shares in the last quarter. Pinnacle Bank raised its stake in shares of Mylan by 66.4% in the first quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock valued at $30,000 after acquiring an additional 423 shares in the last quarter. Global Retirement Partners LLC raised its stake in shares of Mylan by 107.1% in the first quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock valued at $27,000 after acquiring an additional 500 shares in the last quarter. Securian Asset Management Inc raised its stake in shares of Mylan by 1.0% in the first quarter. Securian Asset Management Inc now owns 52,672 shares of the company’s stock valued at $1,493,000 after acquiring an additional 529 shares in the last quarter. Finally, Piedmont Investment Advisors Inc. raised its stake in shares of Mylan by 8.7% in the first quarter. Piedmont Investment Advisors Inc. now owns 8,335 shares of the company’s stock valued at $236,000 after acquiring an additional 670 shares in the last quarter. Institutional investors own 83.77% of the company’s stock.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

See Also: How does the Beige Book influence monetary policy?

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.